Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

NCT00821080 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00821080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00821080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2008
Completion date
February 28, 2015
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma